pharmaphorum5 年
Shield Therapeutics soars on FDA approval of iron deficiency drug
The London-based company said the FDA had approved its lead product Ferracru/Accrufer (ferric maltol) in a market that could be worth $1 billion annually. The FDA approved the product for ...
Proactive Investors3 年
Shield Therapeutics PLC takes bold approach in the US
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer ® /Feraccru ® (ferric maltol).